OraSure Technologies, Inc. (NASDAQ: OSUR), a healthcare company specializing in medical instruments and diagnostic solutions, saw its stock close at $3.16, marking a 1.25% decline from the previous session. The update is important for investors monitoring mid-cap healthcare companies with fluctuating trading volumes.
- Company Overview
- Stock Performance
- Market Position and Sector
- Governance and Leadership
- Key Financial Data
- FAQ
- Conclusion
- Disclaimer
- Official Announcement
Company Overview
OraSure Technologies, Inc., incorporated in 2000 and headquartered in Bethlehem, Pennsylvania, develops, manufactures, and markets oral fluid diagnostic products and specimen collection devices. Operating through its Diagnostics and Molecular Solutions segments, its product portfolio includes rapid tests for HIV, HCV, and Ebola, as well as COVID-19 molecular and antigen testing devices. The company also offers genomic and microbiome collection products for research and commercial applications.
Its brands, including InteliSwab, OraQuick, Oragene, and OMNIgene, have established presence in clinical laboratories, public health organizations, and commercial sectors in the United States and internationally.
Stock Performance
On the latest trading day, OSUR closed at $3.16, down $0.04 (-1.25%) from the previous session. This change reflects modest downward pressure. The stock has traded between $2.36 and $4.60 over the last 52 weeks, emphasizing volatility consistent with medium-sized healthcare companies facing demand shifts in diagnostics.
Trading volume stood at 409,552 shares, below its average volume of 616,153 shares, suggesting slightly lower investor engagement in the session. Since OraSure does not distribute dividends (last dividend: $0), investors rely primarily on capital appreciation for returns.
Market Position and Sector
OraSure participates in the Medical – Instruments & Supplies industry, within the healthcare sector. This segment faces consistent regulatory oversight and shifting demand patterns due to evolving public health needs. Competitiveness is driven by innovation in diagnostics, supply chain resilience, and adaptability to global healthcare priorities.
With a market capitalization of approximately USD 231.1 million, OraSure is positioned in the small to mid-cap range. This category often represents companies with room for growth but potentially higher volatility compared to large-cap entities.
Governance and Leadership
The company is led by CEO Carrie Eglinton Manner, guiding specific strategies in innovation, regulatory compliance, and market expansion. Leadership plays a central role in balancing the commercial aspects with compliance in healthcare diagnostics.
OraSure’s governance structure supports its dual focus on diagnostics and molecular solutions, enabling targeted investment in public health-related technologies.
Key Financial Data
Trading Details
- Exchange: NASDAQ Global Select
- Symbol: OSUR
- ISIN: US68554V1089
- CUSIP: 68554V108
- Currency: USD
- IPO Date: November 17, 1986
Data Insights
- Share Price: USD 3.16
- Market Cap: USD 231.1 million
- 52-week Range: USD 2.36 – USD 4.60
- Daily Change: -0.04 (-1.25%)
- Volume: 409,552 shares
- Average Volume: 616,153 shares
- Dividend: None
These indicators give investors a clear picture of liquidity, volatility, and overall market sentiment regarding OraSure. Comparisons with industry peers may highlight relative strength or areas for improvement in capital structure.
FAQ
- Does OraSure Technologies pay dividends? No, the company currently does not pay dividends.
- Where is the company headquartered? Bethlehem, Pennsylvania, United States.
- How many employees does OraSure have? Approximately 501 full-time employees.
- On which exchange is OSUR listed? NASDAQ Global Select Market.
- What is the company’s industry classification? Medical – Instruments & Supplies, Healthcare sector.
Conclusion
OraSure Technologies presents a profile of a mid-cap healthcare device company maintaining activity in specialized diagnostics markets. The recent 1.25% share price decline aligns with broader fluctuations seen in healthcare stocks. Given its absence of dividend distributions, investors should assess growth prospects and innovation pipeline while monitoring sector-specific developments.
Disclaimer
This article is for informational purposes only and does not constitute financial advice or recommendations. Investors should perform their own due diligence before making decisions.
Official Announcement
For full information about the company, see the link below.